A randomised, open-label, phase 2 study of the IDO1 inhibitor epacadostat (INCB024360) versus tamoxifen as therapy for biochemically recurrent (CA-125 relapse)–only epithelial ovarian cancer, primary…

Overview of attention for article published in Gynecologic Oncology, July 2017

Altmetric Badge

About this Attention Score

In the top 25% of all research outputs scored by Altmetric
High Attention Score compared to outputs of the same age (80th percentile)
Good Attention Score compared to outputs of the same age and source (74th percentile)

Mentioned by

twitter: 4 X users

patent: 2 patents

Readers on

mendeley: 100 Mendeley

So far, Altmetric has seen 4 X posts from 4 X users, with an upper bound of 11,406 followers.

Open Access UCL Research: A randomised, open-label, phase 2 study of the IDO1 inhibitor epacadostat (INCB024360) versus tamoxifen as therapy for biochemically recurrent (CA-125 relapse)-only epithelial ovarian cancer, primary peritoneal carcinoma ... h…

... as if there would have been no warning signs ... Here https://t.co/wMH2UySVVz And here https://t.co/gUFlLMxC4N (Table 4!!)

RT @DrPaulyDeSantis: Just Published: A Ph 2 study of the IDO1 inhibitor epacadostat vs tamoxifen as therapy for recurrent OvCancer $INCY ht…

Just Published: A Ph 2 study of the IDO1 inhibitor epacadostat vs tamoxifen as therapy for recurrent OvCancer $INCY https://t.co/GuFFfH9SXj

This page shows the most recent X posts that mention this research output. Click here to find out how to access more activity.